STOCK TITAN

[Form 4] Boston Scientific Corp. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

UnitedHealth Group (UNH) – Form 4 insider transaction.

CEO and Director Stephen J. Hemsley reported the acquisition of 198 deferred stock units on 07/01/2025 as part of his regular quarterly board compensation. These units are immediately vested but must be held until he leaves the Board, and the filing shows $0 purchase price (non-cash grant).

Following the award, Hemsley’s beneficial ownership stands at:

  • 374,605.942 shares held directly
  • 349.7176 shares held through the company 401(k)
  • 735,115 shares held via family trusts

No derivative securities were reported, and there were no sales or open-market purchases. The filing appears to be routine compensation-related and does not indicate any change in strategic outlook or financial performance for UnitedHealth Group.

UnitedHealth Group (UNH) – Transazione interna Form 4.

Il CEO e Direttore Stephen J. Hemsley ha segnalato l'acquisizione di 198 unità di azioni differite il 01/07/2025 come parte della sua normale retribuzione trimestrale da membro del consiglio. Queste unità sono immediatamente maturate ma devono essere mantenute fino alla sua uscita dal Consiglio, e la dichiarazione indica un prezzo di acquisto pari a $0 (concessione non in denaro).

Dopo l'assegnazione, la proprietà effettiva di Hemsley è la seguente:

  • 374.605,942 azioni detenute direttamente
  • 349,7176 azioni detenute tramite il piano 401(k) aziendale
  • 735.115 azioni detenute tramite trust familiari

Non sono stati segnalati titoli derivati, né vendite o acquisti sul mercato aperto. La dichiarazione sembra essere una normale operazione legata alla retribuzione e non indica alcuna modifica nella strategia o nella performance finanziaria di UnitedHealth Group.

UnitedHealth Group (UNH) – Transacción interna Formulario 4.

El CEO y Director Stephen J. Hemsley reportó la adquisición de 198 unidades de acciones diferidas el 01/07/2025 como parte de su compensación trimestral habitual por ser miembro de la junta. Estas unidades están inmediatamente adquiridas pero deben mantenerse hasta que deje la Junta, y el informe muestra un precio de compra de $0 (concesión no monetaria).

Tras la adjudicación, la propiedad beneficiaria de Hemsley es:

  • 374,605.942 acciones en posesión directa
  • 349.7176 acciones a través del plan 401(k) de la empresa
  • 735,115 acciones en fideicomisos familiares

No se reportaron valores derivados, ni ventas o compras en el mercado abierto. El informe parece ser una compensación rutinaria y no indica ningún cambio en la perspectiva estratégica o el desempeño financiero de UnitedHealth Group.

UnitedHealth Group (UNH) – 내부자 거래 Form 4 보고.

CEO 겸 이사인 Stephen J. Hemsley가 2025년 7월 1일 정기 분기 이사회 보수의 일환으로 198개의 이연 주식 단위를 취득했다고 보고했습니다. 이 단위들은 즉시 권리 확정되었으나 그가 이사회에서 떠날 때까지 보유해야 하며, 보고서에는 구매 가격이 $0로 기재되어 있습니다(현금이 아닌 보조금).

수령 후 Hemsley의 실질 소유 주식은 다음과 같습니다:

  • 374,605.942주 직접 보유
  • 349.7176주 회사 401(k) 플랜을 통해 보유
  • 735,115주 가족 신탁을 통해 보유

파생 증권은 보고되지 않았으며, 매도나 공개 시장 매수도 없었습니다. 이번 보고는 보수 관련 일상적인 사항으로 보이며 UnitedHealth Group의 전략적 전망이나 재무 성과에 변화를 시사하지 않습니다.

UnitedHealth Group (UNH) – Transaction d’initié Formulaire 4.

Le PDG et administrateur Stephen J. Hemsley a déclaré l’acquisition de 198 unités d’actions différées le 01/07/2025 dans le cadre de sa rémunération trimestrielle habituelle au conseil d’administration. Ces unités sont immédiatement acquises mais doivent être conservées jusqu’à son départ du conseil, et le dépôt indique un prix d’achat de 0 $ (attribution non monétaire).

Après cette attribution, la propriété bénéficiaire de Hemsley se compose de :

  • 374 605,942 actions détenues directement
  • 349,7176 actions détenues via le plan 401(k) de l’entreprise
  • 735 115 actions détenues par des trusts familiaux

Aucun titre dérivé n’a été déclaré, et il n’y a eu ni ventes ni achats sur le marché libre. Le dépôt semble être lié à une rémunération routinière et n’indique aucun changement dans la stratégie ou la performance financière de UnitedHealth Group.

UnitedHealth Group (UNH) – Insider-Transaktion Form 4.

CEO und Direktor Stephen J. Hemsley meldete am 01.07.2025 den Erwerb von 198 aufgeschobenen Aktienanteilen im Rahmen seiner regulären vierteljährlichen Vorstandsvergütung. Diese Einheiten sind sofort unverfallbar, müssen jedoch bis zu seinem Ausscheiden aus dem Vorstand gehalten werden. Die Meldung weist einen Kaufpreis von 0 $ aus (nicht in bar gewährte Zuwendung).

Nach der Zuteilung beläuft sich Hemsleys wirtschaftliches Eigentum auf:

  • 374.605,942 direkt gehaltene Aktien
  • 349,7176 Aktien über den firmeninternen 401(k)-Plan
  • 735.115 Aktien über Familienstiftungen

Es wurden keine Derivate gemeldet, ebenso keine Verkäufe oder Käufe am offenen Markt. Die Meldung scheint routinemäßige, vergütungsbezogene Vorgänge zu betreffen und deutet nicht auf eine Änderung der strategischen Ausrichtung oder der finanziellen Lage von UnitedHealth Group hin.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director compensation grant; immaterial size, neutral signal.

The 198-unit deferred stock grant to CEO/Director Stephen Hemsley is a standard quarterly award that vests immediately but is locked up until board service ends. With existing direct and indirect ownership exceeding 1.1 million shares, this grant is de-minimis (<0.02 % of his holdings) and involves no cash outlay. It neither changes insider sentiment nor alters the company’s share supply. For investors, the filing is non-impactful and should not influence valuation or trading decisions.

UnitedHealth Group (UNH) – Transazione interna Form 4.

Il CEO e Direttore Stephen J. Hemsley ha segnalato l'acquisizione di 198 unità di azioni differite il 01/07/2025 come parte della sua normale retribuzione trimestrale da membro del consiglio. Queste unità sono immediatamente maturate ma devono essere mantenute fino alla sua uscita dal Consiglio, e la dichiarazione indica un prezzo di acquisto pari a $0 (concessione non in denaro).

Dopo l'assegnazione, la proprietà effettiva di Hemsley è la seguente:

  • 374.605,942 azioni detenute direttamente
  • 349,7176 azioni detenute tramite il piano 401(k) aziendale
  • 735.115 azioni detenute tramite trust familiari

Non sono stati segnalati titoli derivati, né vendite o acquisti sul mercato aperto. La dichiarazione sembra essere una normale operazione legata alla retribuzione e non indica alcuna modifica nella strategia o nella performance finanziaria di UnitedHealth Group.

UnitedHealth Group (UNH) – Transacción interna Formulario 4.

El CEO y Director Stephen J. Hemsley reportó la adquisición de 198 unidades de acciones diferidas el 01/07/2025 como parte de su compensación trimestral habitual por ser miembro de la junta. Estas unidades están inmediatamente adquiridas pero deben mantenerse hasta que deje la Junta, y el informe muestra un precio de compra de $0 (concesión no monetaria).

Tras la adjudicación, la propiedad beneficiaria de Hemsley es:

  • 374,605.942 acciones en posesión directa
  • 349.7176 acciones a través del plan 401(k) de la empresa
  • 735,115 acciones en fideicomisos familiares

No se reportaron valores derivados, ni ventas o compras en el mercado abierto. El informe parece ser una compensación rutinaria y no indica ningún cambio en la perspectiva estratégica o el desempeño financiero de UnitedHealth Group.

UnitedHealth Group (UNH) – 내부자 거래 Form 4 보고.

CEO 겸 이사인 Stephen J. Hemsley가 2025년 7월 1일 정기 분기 이사회 보수의 일환으로 198개의 이연 주식 단위를 취득했다고 보고했습니다. 이 단위들은 즉시 권리 확정되었으나 그가 이사회에서 떠날 때까지 보유해야 하며, 보고서에는 구매 가격이 $0로 기재되어 있습니다(현금이 아닌 보조금).

수령 후 Hemsley의 실질 소유 주식은 다음과 같습니다:

  • 374,605.942주 직접 보유
  • 349.7176주 회사 401(k) 플랜을 통해 보유
  • 735,115주 가족 신탁을 통해 보유

파생 증권은 보고되지 않았으며, 매도나 공개 시장 매수도 없었습니다. 이번 보고는 보수 관련 일상적인 사항으로 보이며 UnitedHealth Group의 전략적 전망이나 재무 성과에 변화를 시사하지 않습니다.

UnitedHealth Group (UNH) – Transaction d’initié Formulaire 4.

Le PDG et administrateur Stephen J. Hemsley a déclaré l’acquisition de 198 unités d’actions différées le 01/07/2025 dans le cadre de sa rémunération trimestrielle habituelle au conseil d’administration. Ces unités sont immédiatement acquises mais doivent être conservées jusqu’à son départ du conseil, et le dépôt indique un prix d’achat de 0 $ (attribution non monétaire).

Après cette attribution, la propriété bénéficiaire de Hemsley se compose de :

  • 374 605,942 actions détenues directement
  • 349,7176 actions détenues via le plan 401(k) de l’entreprise
  • 735 115 actions détenues par des trusts familiaux

Aucun titre dérivé n’a été déclaré, et il n’y a eu ni ventes ni achats sur le marché libre. Le dépôt semble être lié à une rémunération routinière et n’indique aucun changement dans la stratégie ou la performance financière de UnitedHealth Group.

UnitedHealth Group (UNH) – Insider-Transaktion Form 4.

CEO und Direktor Stephen J. Hemsley meldete am 01.07.2025 den Erwerb von 198 aufgeschobenen Aktienanteilen im Rahmen seiner regulären vierteljährlichen Vorstandsvergütung. Diese Einheiten sind sofort unverfallbar, müssen jedoch bis zu seinem Ausscheiden aus dem Vorstand gehalten werden. Die Meldung weist einen Kaufpreis von 0 $ aus (nicht in bar gewährte Zuwendung).

Nach der Zuteilung beläuft sich Hemsleys wirtschaftliches Eigentum auf:

  • 374.605,942 direkt gehaltene Aktien
  • 349,7176 Aktien über den firmeninternen 401(k)-Plan
  • 735.115 Aktien über Familienstiftungen

Es wurden keine Derivate gemeldet, ebenso keine Verkäufe oder Käufe am offenen Markt. Die Meldung scheint routinemäßige, vergütungsbezogene Vorgänge zu betreffen und deutet nicht auf eine Änderung der strategischen Ausrichtung oder der finanziellen Lage von UnitedHealth Group hin.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brown Vance R

(Last) (First) (Middle)
300 BOSTON SCIENTIFIC WAY

(Street)
MARLBOROUGH MA 01752-1234

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, GC and Corp. Secretary
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 M 4,036 A $0.0000(1) 35,403 D
Common Stock 07/01/2025 F 1,952 D $104.78 33,451 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 07/01/2025 M 4,036 (2) 07/01/2025(2) Common Stock 4,036 $0.0000 0.0000 D
Explanation of Responses:
1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.
/s/ Susan Thompson, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Stephen J. Hemsley acquire on 07/01/2025?

198 deferred stock units were granted as part of regular board compensation.

What is Stephen J. Hemsley’s total direct ownership in UNH after the transaction?

He now holds 374,605.942 shares directly.

Were any UnitedHealth Group shares sold in this Form 4 filing?

No. The filing reports only an acquisition; no sales occurred.

Does the Form 4 indicate open-market purchases by the CEO?

No. The units were a non-cash, board compensation grant with a $0 price.

How many shares does Hemsley hold indirectly through trusts and the 401(k)?

He holds 735,115 shares via trusts and 349.7176 shares in the 401(k).
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Latest News

BSX Latest SEC Filings

BSX Stock Data

154.29B
1.47B
0.2%
93.36%
0.87%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH